ABSTRACT BACKGROUND: There is increasing interest in using neurobiological measures to inform psychiatric nosology. It is unclear at the present time whether anxiety and depression are neurobiologically distinct or similar processes. It is also unknown if the best way to examine these disorders neurobiologically is by contrasting categorical definitions or by examining symptom dimensions. METHODS: A cross-sectional neuroimaging study was conducted of patients with generalized anxiety disorder (GAD), major depressive disorder (MDD), comorbid GAD and MDD (GAD/MDD), or neither GAD nor MDD (control subjects). There were 90 participants, all medication-free (17 GAD, 12 MDD, 23 GAD/MDD, and 38 control subjects). Diagnosis/category and dimensions/symptoms were assessed to determine the best fit for neurobiological data. Symptoms included general distress, common to anxiety and depression, and anxiety-specific (anxious arousal) or depression-specific (anhedonia) symptoms. Low-frequency (.008-.1 Hz) signal amplitude and functional connectivity analyses of resting-state functional magnetic resonance imaging data focused on a priori cortical and subcortical regions of interest. RESULTS: Support was found for effects of diagnosis above and beyond effects related to symptom levels as well as for effects of symptom levels above and beyond effects of diagnostic categories. The specific dimensional factors of general distress and anxious arousal as well as a diagnosis of MDD explained unique proportions of variance in signal amplitude or functional connectivity. CONCLUSIONS: Using resting-state functional magnetic resonance imaging, our data show that a single conceptual model alone (i.e., categorical diagnoses or symptom dimensions) provides an incomplete mapping of psychopathology to neurobiology. Instead, the data support an additive model that best captures abnormal neural patterns in patients with anxiety and depression.
A key issue for understanding the pathophysiology of mental illness as well as its nosology is the need to determine how symptoms relate to abnormal brain processes (i.e., putative mechanisms) (1) . This issue is particularly salient for mood and anxiety disorders because comorbidity between disorders is the normative clinical course (2, 3) . One view that treats anxiety and depression as reflecting the same core process is supported by concordance studies indicating a shared genetic diathesis between generalized anxiety disorder (GAD) and major depressive disorder (MDD) (4, 5) . Symptom-based evidence also suggests a general class of "anxious-misery" disorders including GAD and MDD (6) (7) (8) . However, these disorders can be differentiated with respect to illness predictors and symptoms (3, (9) (10) (11) . Comparisons between GAD and MDD indicate greater emotion intensity and goal motivation in GAD and lower positive affect in MDD, among other factors (10) .
Not only is it unclear to what degree GAD and MDD are similar or different as disorders, but also it is unclear whether categorical definitions of GAD and MDD best capture abnormalities. Many authors have argued for understanding anxiety and depression as a set of distinct and overlapping dimensions of dysfunction (12, 13) . One of the most well-known models (13) (14) (15) proposes a tripartite organization: a shared general factor (general negative affect or distress) and two specific factors-anxious arousal (more central to anxiety) and low positive affect or anhedonia (more central to depression).
Complicating a clearer understanding of the neurobiology of anxiety and depressive disorders is the fact that few studies directly compare patients across these diagnostic groups (16) (17) (18) . In a more recent study, we found that only patients with GAD (with or without MDD) showed a behavioral deficit in emotion regulation; this was not present for patients with MDD only (19) . This deficit reflected an abnormality in cingulateamygdala circuitry normally required for this task (20) as well as a unique (compensatory) pattern of activation in patients with MDD only. In a study of anxious and depressed adolescents, Beesdo et al. (21) found both common and disorder-specific abnormalities in amygdala activation during emotional face processing. All patients had greater amygdala activation to fear faces when focused on their own emotions, but facial affect interactions divided patients into complex patterns during passive viewing.
Broadly comparing anxiety and depression, it may be advantageous to examine task-independent brain activity, allowing assessment across brain regions that may not be involved in a particular task. A powerful tool for doing so is resting-state functional magnetic resonance imaging (fMRI), in which intrinsic activity and connectivity of brain circuitry can be examined across many brain systems and regions (22) . Separate resting-state studies of patients with GAD and patients with MDD have implicated abnormalities in many structures, including amygdala, hippocampus, ventral striatum, insula, dorsal and subgenual anterior cingulate (ACC), and dorsolateral and medial prefrontal cortices (DLPFC, mPFC) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . It is still unclear how these brain areas covary in patients as a function of pathophysiology. Analyses of the relationship between anxiety symptoms in healthy subjects and resting-state brain activity have demonstrated effects in many of these same regions (33) (34) (35) . However, to our knowledge, anxiety and depression have never been directly compared using task-independent resting-state methods, and categorical and dimensional conceptualizations have not been evaluated in a single cohort.
In this study, we sought to answer the following three questions: 1) Are neural signatures of anxiety and depression consistent with their being common or distinct neurobiological processes? 2) What are the relative contributions of categorical and dimensional formulations of anxiety and depression on neural processes? 3) Which brain regions are most strongly related to anxiety and depression? We analyzed models of combined categorical and dimensional factors according to the amplitude of the low-frequency resting-state signal within each region as well as functional connectivity between regions, measured as time series correlations between region pairs. All participants were medication-free when scanned.
To ensure a comprehensive categorical analysis, we recruited participants with a diagnosis of GAD, with a diagnosis of MDD, with both diagnoses, or with neither diagnosis. Because these three groups overlapped by symptom profiles, we were similarly able to conduct dimensional analyses. For the categorical analyses, separate predictors corresponding to a diagnosis of GAD or MDD allowed us to examine disorderspecific effects, whereas a single predictor corresponding to either diagnosis tested for a general patient deficit relative to controls. By having partially overlapping patient groups and modeling diagnoses together, we allowed for the possibility that abnormalities in one diagnostic group (e.g., MDD) could be best explained by its frequent comorbid diagnosis (e.g., GAD) or the possibility that individual diagnoses could explain independent neural abnormalities even after accounting for the presence of the other diagnosis. For dimensional analyses, we used the Mood and Anxiety Symptom Questionnaire (36) , developed to assess the common symptom domain of general distress elevated across anxiety and depressive disorders, and specific domains of anxious arousal and anhedonia in accordance with the dimensional tripartite model of anxiety and depression. Three separate models were run for each metric (signal amplitude and functional connectivity): individual categorical and dimensional models were first run to establish possible relationships between these factors and brain measures. Next, to understand further the primacy of either categorical or dimensional measures for explaining variability in brain measures, we combined categorical and dimensional measures in a simultaneous regression. This strategy allowed for uncovering additive or overlapping predictors across categories and dimensions depending on which measures were the strongest predictors and which explained unique brain variability after accounting for the other factors.
METHODS AND MATERIALS Participants
After providing informed consent, 90 subjects participated in this study; these subjects largely overlapped with the subjects reported in our articles on task-based fMRI (19, 23, 37) . Current-episode DSM-IV-based psychiatric diagnoses (38) were determined with the Mini International Neuropsychiatric Interview (39, 40) . Participants included 38 healthy control subjects, 17 subjects with a primary diagnosis of GAD and no MDD, 12 subjects with a primary diagnosis of MDD and no GAD, and 23 subjects with both diagnoses (see Table S1 in Supplement 1 for other comorbidities). Exclusion criteria were the presence of substance abuse or posttraumatic stress disorder; a history of a neurologic disorder or severe mental illness (psychosis or bipolar); a history of head trauma or loss of consciousness; claustrophobia; or regular use of benzodiazepines, opiates, or thyroid medications. All control subjects were free of current or past Axis I conditions or psychiatric medications. No patient took a benzodiazepine within 48 hours of the scan, and all patients were free of antidepressant medication for .6 weeks.
fMRI Data Acquisition and Processing
Neuroimaging data were acquired on a 3-Tesla GE Signa scanner (GE Healthcare, Milwaukee, Wisconsin) using a custom-built eight-channel head coil. Functional data were acquired in 29 axial slices (4.0-mm thickness, .5-mm gap) across the whole brain using a T2*-weighted gradient echo spiral (in/out) sequence (repetition time 5 2 sec; echo time 5 30 msec; flip angle 5 801; 1 interleaf; field of view 5 22 cm; 64 3 64 matrix; 236 volumes) (41) . Instructions for the 8-min resting-state scan asked participants to keep still, keep their eyes closed, and let their mind wander. An automated highorder shim for spiral acquisitions was used before acquiring fMRI data (42) . A high-resolution T1-weighted threedimensional inversion recovery spoiled gradient recoil anatomic scan (inversion time 5 300 msec; repetition time 5 8 msec; echo time 5 3.6 msec; flip angle 5 151; field of view 5 22 cm; 124 coronal plane slices; matrix 5 256 3 192; 2 excitations; acquired resolution 5 1.5 mm 3 0.9 mm 3 1.1 mm) was acquired in the same session as fMRI data.
Physiologic variability recorded in respiration and heart rate pulse oximetry was used for fMRI data correction as an initial preprocessing step (image based using acquisition timing relative to phases of cardiac and respiratory cycles) (43 Oxford, Oxford, United Kingdom] defaults) and then slice timing correction was applied to functional images; no participant had movement .3 mm translation or 3 degrees of rotation (cumulative, absolute value). Affine registration of the functional to structural images was combined with nonlinear normalization between T1 and MNI152 space for functional images using standard settings for the FSL 5.0 FNIRT tool (http://fsl.fmrib.ox. ac.uk/fsl/fslwiki/). Functional images were smoothed with a 5-mm full width at half maximum Gaussian filter. Time series data were band-pass filtered (.008-.1 Hz) and entered in a firstlevel fixed-effects general linear model for functional connectivity calculation, covarying for white matter and cerebrospinal fluid signal (see Supplement 1 for analyses of this noise estimate) as well as residual motion parameters. Fisher's r-toz calculation on functional connectivity images was performed before average connectivity values were extracted across each region of interest (ROI). The Data Processing Assistant for Resting-State fMRI (http://rfmri.org/DPARSF) toolbox (44) was used on unfiltered data to generate spectral power amplitudes in the low-frequency band (.008-.1 Hz). The root mean square of the power spectrum density in the chosen band was standardized to the average amplitude of the full gray matter mask (voxel/average rest of brain). Then fractional amplitude was calculated relative to the full power spectrum (low frequency/full band) defined by the fMRI sampling rate (0-.25 Hz for repetition time 5 2.0) and was used for ROI extraction and analysis, referred to hereafter as "signal amplitude."
ROI Selection
A priori ROI were defined ( Figure 1 ) where possible by anatomic boundaries, including the hippocampus (70% probability threshold in the Harvard-Oxford atlas) (45), basolateral and centromedial amygdala (maximum probability defined in our previous article, from a cytoarchitectonically defined atlas) (23, 46) , and the ventral striatum (based on subcortical anatomic segmentation atlas (47) with a small overlap in the left hemisphere with the subgenual ACC ROI removed). Amygdala extractions used a combined basolateral and centromedial mask because separating the amygdala by subregion did not alter findings. The subgenual ACC ROI was an 8-mm gray matter-masked sphere around a peak coordinate (x, y, z: 2, 18, 28) associated with MDD abnormalities averaged from 14 fMRI studies (48) . The ROI for the dorsal ACC, DLPFC, mPFC, and fronto-insular cortex were derived by thresholding resting-state independent component maps from a separate cohort of healthy subjects to yield 1000 voxel clusters for each region to allow them approximately equal weight as seeds for cross-region comparisons, in accordance with the topography of typical resting-state networks (49) . For nonmidline regions, we averaged signal from left-sided and right-sided ROI, given no laterality predictions and an exploratory principal component analysis indicating left and right hemisphere signal amplitude and connectivity loading consistently on the same factor.
Statistical Analyses
Mean low-frequency signal amplitudes and functional connectivity (Z score) values for each ROI were determined in Montreal Neurological Institute space. Using SPSS software (SPSS, Inc., Chicago, Illinois), we conducted principal components analyses with quartimax rotation for data reduction to limit multiple comparisons and to recognize that dimensional and categorical constructs related to affective disorders probably involve several distributed neural processes. For specific component interactions with categorical or dimensional variables, stepwise regressions were included to determine standardized β (sβ) and significance values for individual predictors (stepping criteria, entry, .05; removal, .10). The optimal number of extracted components was determined by eigenvalues .1. Identical analyses were run separately for signal amplitude and functional connectivity Z scores. Resting-state data were analyzed using general linear models, including principal components as repeated measures with a Greenhouse-Geisser correction, as described in the Results. χ 2 and t tests were used where noted.
RESULTS

Sample Characteristics
No significant differences in age, education, gender, or average head motion (x, y, z directions) were found using either categorical or dimensional models (all p . .08) (Table S1 in Supplement 1). As shown in Figure 2 , there was partial overlap in symptom scores between control subjects and 
Low-Frequency Signal Amplitudes
To minimize the number of comparisons, our principal components data reduction across ROI yielded three principal components. As shown by rotated component loadings in Table 1 , these involve primarily limbic/paralimbic regions (amygdala, hippocampus, ventral striatum, subgenual ACC), DLPFC/mPFC, and cingulo-opercular regions (dorsal cingulate and fronto-insular cortex). We entered these three components as repeated measures into three general linear models examining 1) categorical predictors only (GAD, MDD), 2) dimensional predictors only (anxious arousal, anhedonia, general distress), and 3) categorical and dimensional predictors together to determine the strongest independent predictors of signal amplitude. Figure 3A , the GAD by principal component interaction reflected a GAD effect specifically on limbic/paralimbic regions, wherein greater low-frequency signal amplitudes were seen for participants with GAD compared with participants without GAD [t 88 5 2.5, p 5 .015; other p . .28]. In a stepwise model, only GAD was a significant predictor of limbic/paralimbic signal (sβ 5 .255, p 5 .015).
We also examined in a repeated measures model whether patients as a whole differed from control subjects in lowfrequency signal amplitudes, but we found no main effect of patient versus control subject or interaction with principal component (all p . .40).
For (Figure 3B) , driving the full model interaction.
Despite the fact that symptom scores were continuously distributed and partially overlapping between patients and control subjects, effects of dimensional predictors across participants may still reflect higher symptom scores in patients. We tested a model that included the three dimensional predictors, a categorical predictor for patient versus control subject, and the interactions between the categorical patient predictor and dimensional symptom predictors. Nonetheless, we still found the significant interaction between principal component and general distress [ Finally, we tested the combination of categorical and dimensional predictors to determine which predictors account for the greatest variance in low-frequency signal. Because both GAD and general distress were associated with greater limbic/paralimbic signal in the separate categorical and dimensional models, respectively, we were particularly interested in which was the stronger predictor in a combined model. We found that the principal component by general distress interaction remained significant [F 2,168 5 5.0, p 5 .008], again driven by a positive relationship with limbic/paralimbic signal ( Figure 3C ), whereas the GAD main effect was reduced to nonsignificance [F 1,84 5 .1, p 5 .824) indicating that distress substantially overlapped with the GAD effect and was an even better predictor of limbic/paralimbic low-frequency signal amplitude (forced entry Figure 3D ; Figure S1 in Supplement 1). After accounting for relationships between signal amplitude and all other factors from each of the three symptom scales and GAD diagnosis (estimated marginal means), MDD was the only factor associated with reduced signal amplitudes. Parallel analyses on the 52 patients only revealed highly similar findings (Supplement 1), demonstrating consistency and robustness of findings.
Functional Connectivity
Principal component data reduction on all ROI pairwise functional connectivity correlations yielded six components ( Table 1 ). The first component captured cortical connectivity (nonsubcortical); the second, subgenual cingulate and ventral Neurobiological Signatures of Anxiety and Depression in Resting-State fMRI striatum connectivity; the third, amygdala subcortical connectivity; the fourth, positive amygdala prefrontal (and negative fronto-opercular subcortical) connectivity; the fifth, prefrontal fronto-opercular connectivity; and the sixth, amygdala to fronto-opercular connectivity. Entering these into a repeated measures model with only categorical predictors did not produce any significant findings (all p . .23 Figure 4A ). We were especially interested in whether this relationship held when controlling for diagnoses in the same model. 
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In the model with both categorical and dimensional predictors, the component by anxious arousal interaction was marginally significant [ 
DISCUSSION
To our knowledge, this is the first study to compare directly anxiety and depressive disorders with resting-state fMRI and to explore explicitly both categorical and dimensional conceptualizations of these conditions together relative to one another. Our findings lend support for both commonalities and distinctions between anxiety and depression. These findings suggest that neither a categorical nor a dimensional model of anxiety and depression explains neurobiology to the exclusion of the other. Rather, mapping the affective pathology onto neurobiological substrates requires combining categorical and dimensional specifications of anxiety and depressive disorders. The combination accounted for patterns of overlapping and independent predictors of restingstate fMRI brain measures. More specifically, our data argue that general distress increases limbic/paralimbic lowfrequency signal amplitudes, whereas MDD diagnosis drives signal down across the brain areas we studied. In terms of functional connectivity between ROI, anxious arousal was associated with greater subgenual ACC/ventral striatum connectivity, whereas MDD was associated with reduced connectivity in this same circuit when covarying symptoms and GAD diagnosis. The anxiety and distress correlations remained significant with or without covarying symptoms and diagnoses. Both relationships were also significant in the patient group alone indicating relevance to affective pathology. The regions most important for understanding both categorical and dimensional aspects of anxiety and depression were the amygdala, ventral striatum, hippocampus, and subgenual ACC. These regions are consistently implicated in anxiety-relevant and depression-relevant processes, such as threat processing, reward and motivation, affect regulation, and memory.
With regard to whether anxiety and depression are components of a single psychopathologic process or reflect distinct processes, we found that categorical diagnoses MDD and GAD are associated with distinct resting-state alterations. However, the GAD effect (greater limbic/paralimbic signal) is better attributed to the symptom dimension of general distress. General distress can be considered a measure of disordernonspecific broad negative affect, and similar results (not shown) are found by replacing this measure with the first principal component from a principal component analysis across many depression and anxiety measures [Beck Anxiety and Depression Inventories (50, 51) , Penn State Worry Questionnaire (52), Spielberger Trait Anxiety Inventory (53)]. However, the categorical effect of MDD was especially strong in patients and represented a nonoverlapping suppression of signal amplitude across ROI. In functional connectivity, anxious arousal emerged as a strong independent predictor of increased subgenual ACC/ventral striatum connectivity in the opposite direction of an MDD effect (covarying GAD diagnosis and other symptoms). We found diagnosis-specific perturbations related to MDD as well as diagnosis-nonspecific perturbations related Neurobiological Signatures of Anxiety and Depression in Resting-State fMRI to general distress and anxious arousal. Although there were small differences between models, results were strikingly consistent at multiple levels (full group and patients alone) and with or without covarying other categorical/dimensional factors. Our findings have implications not only for how neurobiology can inform psychopathology and its nosology but also for emerging theoretical models of mental illness. A DSM-type approach relies on specific symptom criteria for establishing a categorical diagnosis, whereas an approach such as the Research Domain Criteria from the National Institute of Mental Health advocates for a dimensional organization. Our data suggest that use of only a single conceptual framework (i.e., categorical diagnoses or symptom dimensions) provides an incomplete answer. Although it may, in principle, be possible to establish dimensions that capture the MDD diagnosis effect, it is apparent that one of the best-described attempts to do so (i.e., the tripartite model) was insufficient for this application. As a predictor for our brain measures, GAD was subsumed under general distress. Also, MDD emerged primarily as an effect only when accounting for GAD and dimensional scales (combined model). One possibility is that symptoms are especially strong predictors of resting brain abnormalities but could partially obscure a weaker but distinct MDD categorical abnormality. The functional relevance of both dimensional and categorical predictors should be carried forward as an investigation for future research. The patient only correlation between distress and DLPFC/mPFC connectivity did not reflect an abnormality in models with healthy controls but nevertheless may reflect important within-patient clinical phenomena given especially the importance of these regions for mapping individual differences in MDD response to transcranial magnetic stimulation (48, 54) .
Methodologically, it is notable that our findings suggest unique sources of pathology across domains of low-frequency signal amplitude and low-frequency correlation (functional connectivity) between brain regions implicated in clinical anxiety and depression. Nevertheless, theoretical overlaps can be seen across the two measures. For example, anxious arousal was associated with greater subgenual ACC/ventral striatum connectivity, and general distress was associated with greater signal for a factor that included these brain areas (limbic/ paralimbic factor). Also, an MDD diagnosis was associated broadly with lower signal amplitudes consistent with lower subgenual ACC/ventral striatum connectivity findings for MDD. However, anxious arousal was also associated with lower amygdala connectivity to a specific target (fronto-opercular), and MDD was associated with greater amygdala-to-subcortical connectivity, which represent a seemingly unrelated set of abnormalities. Low-frequency signal amplitude is a reliable fMRI blood oxygen level-dependent derivative (55) sensitive to both stable individual differences (56) and transient brain fluctuations (49) . However, it is used far less frequently than independent component analysis or functional connectivity to study resting brain networks, and the degree of complementarity between signal amplitude and these traditional measures warrants added attention including in the domain of psychopathology.
Limitations of this study include a relatively small sample of patients with MDD alone (see also power calculations in Supplement 1 regarding MDD only effects). Nonetheless, sample sizes were substantial across disorders for comparing effects for anxiety and depression as general groupings. Also, our groups were well educated, on average, which may have influenced findings. Allowing some comorbidity increased the representativeness of our sample but may also have influenced results. A limitation of resting-state fMRI is that the nature of the measures in isolation precludes insight about specific mental processes. Future work will need to extend these findings using tasks more directly tapping functions subserved by key regions identified here and with appropriate manipulations and assessments of mental states related to psychopathology at rest. Resting-state networks are largely stable across behavioral states, levels of consciousness, and species (57), which suggests that resting-state measures may capture consistent mental state differences between patients and healthy individuals. Our data likely speak to broad baseline neuropathology that may be superimposed on or interact with brain signatures of specific mental states (that also may differ by patient group). Additional descriptions of patients using other factors (e.g., cognitive symptoms, perseverative thinking, functional impairment) may explain additional variance compared with these In the combined model, major depressive disorder was associated with reduced subgenual anterior cingulate cortex/ventral striatum connectivity (C) and increased amygdala-subcortical connectivity (D). MDD, major depressive disorder; sgACC, subgenual anterior cingulate cortex; VS, ventral striatum.
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Biological Psychiatry initial models. Similarly, additional brain regions or networks could contribute further evidence of patient abnormalities related to dimensions and categories. Methodologically, increasing the number of transmit/receive coils could improve signal-to-noise ratio and lead to additional findings (perhaps better resolution of amygdala subregional effects). Typical psychiatric medications influence the neural circuitry studied here, and because many patients regularly take these medications, a follow-up study might include patients taking medication to understand how the metrics observed in the present study are influenced by specific medications.
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